Abstract-The notion that eating chocolate would prevent or treat hypertension is appealing to many who produce and enjoy chocolate. Several studies have documented beneficial effects of dark chocolate on insulin action and endothelial function. However, the published studies on chocolate and blood pressure include a relatively small number of subjects, and results are conflicting. In addition, because of secrecy surrounding the production of chocolate and the unique sociocultural context of this popular food, research on efficacy and effectiveness is complex. 4 Prehypertension is associated with a 3.0-fold greater likelihood of progression to hypertension and 1.4-to 2.0-fold greater risk for cardiovascular events than normal blood pressure (BP) Ͻ120/Ͻ80 mm Hg. 5 Lifestyle changes are foundational management for all hypertensive patients and the only management option recommended for most prehypertensives. 4 Hypertension and prehypertension are associated with a cluster of risk factors, including abdominal obesity, hyperinsulinemia, insulin resistance, and vascular dysfunction. 6 -8 Although several lifestyle changes, for example, the Dietary Approaches to Stop Hypertension Eating Plan, 4 are efficacious for lowering BP and improving other risk factors, their effectiveness is limited. In fact, Americans are becoming progressively heavier and their diets less like the Dietary Approaches to Stop Hypertension diet over time. 9,10 Thus, simple and effective lifestyle changes, which would be adopted and maintained by a large proportion of prehypertensives, could reduce the burden of prehypertension and hypertension. Dark chocolate/cocoa may be an intervention that could be implemented and maintained by a large proportion of at-risk individuals. 11 A diverse evidence base suggests that cocoa lowers BP while improving insulin sensitivity, vascular function, and cardiovascular outcomes. 12, 13 Cocoa, BP, and Cardiovascular Disease: An Ecological Perspective The Kuna Indians live on the San Blas Islands off Panama. They consume large quantities of cocoa, and, despite high sodium intake, have a low prevalence of hypertension. Their BP does not rise with age. 14 Kuna Indians who migrate to Panama manifest age-dependent increases of BP and a higher prevalence of hypertension than Kuna Islanders. Thus, Kuna are not genetically protected from hypertension. Kuna Islanders consume Ϸ10 times more cocoa than those in Panama and have Ϸ80% less cardiovascular disease. On the basis of this and other evidence, Corti et al 11 proposed that flavanols, especially epicatechin, in cocoa lower BP and improve vascular function and insulin sensitivity while reducing platelet reactivity.
preferences. Swiss chocolate is "conched" 3-times longer than American chocolate, resulting in a smoother consistency. Differences in chocolate composition among European countries resulted in policy disagreements known as the "chocolate war." National references for chocolate are so important that membership in the European Union includes policies regulating locally produced chocolate. Variations in cocoa processing may impact its biological actions, including the BP effects, which comprise a key limitation in public health recommendations for its consumption to treat and/or prevent hypertension and prehypertension.
Craving and Social Context
While not reaching a chemical addiction, chocolate craving has been reported. 18 Chocolate is often viewed as a special food with cultural norms for when and how much to eat. Recommendations for dark chocolate as a lifestyle intervention for hypertension and prehypertension should consider the social context and potential for producing chocolate craving with a potential for adverse, unintended consequences.
Dark Chocolate and BP
A meta-analysis on cocoa and BP identified 5 studies of adequate quality for inclusion. 12 In these reports, cocoa lowered BP 4.7/2.8 mm Hg (Pϭ0.002/0.006). This commentary and review of dark chocolate and BP included these 5 and 8 other original peer-reviewed studies (Tables 1 and 2 and Figure 1 ). 19 -31 Additional references were found in "Ovid" and "Google" searches (last February 3, 2010) using key words including combinations of "dark chocolate"/ "chocolate"/"cocoa" and "blood pressure"/"hypertension" from review articles identified in the search and discussions with experts in the field. Studies of Ͻ4 days in duration were excluded. Studies were not excluded for methodological concerns, which are noted, thereby allowing the reader to decide the weight that each study should receive.
In the 13 reports, dark chocolate (cocoa) lowered BP in 6 of 7 open-label studies 19 -25 but diastolic BP only in 1 of 6 double-blind studies. 26 -31 Collectively, these reports raise questions on the BP-lowering efficacy of dark chocolate/cocoa, including the possibility that BP effects are negligible. The review provides potential explanations for disparities in BP effects between the various reports that may inform future studies.
Placebo Effect
Because cocoa generally lowered BP in open-label but not double-blind studies (Table 2) , consideration for a placebo effect must be considered. An individual's anticipation of positive or negative effects can impact the targeted health outcome. 32 In general, greater expected benefit leads to greater health improvement. 33 Individual expectations, including influences from family and friends, can impact the health outcome of interventions in ways not accounted for by study design. 34 Placebo effect is an unlikely explanation for BP effects of Ritter dark chocolate in randomized, open-label crossover studies. 20 -24 In nutritional studies, for example, Dietary Approaches to Stop Hypertension, which are impossible to double blind, findings from randomized, open-label crossover design have been accepted as sufficient for guideline recommendations. 4 The magnitude of the BP effects in the studies by Grassi et al 20, 21, 23 are of similar order to those with Dietary Approaches to Stop Hypertension. Although the study by Taubert et al 22 with low-dose Ritter dark chocolate showed a more modest BP reduction, BP change correlated with an NO biomarker.
Taubert et al 22 also noted that double-blind studies with dark chocolate are virtually impossible, because bioactive chemicals in cocoa are bitter. Processing to match taste in flavanol-rich and poor dark chocolate alters the content and composition of cocoa flavanoids, which could alter physiological effects. 22, 35, 36 Crews et al 30 found that 56% of volunteers in the high-and low-polyphenol chocolate/cocoa groups correctly identified their blinded assignment, which is close to chance. Because chocolate/cocoa did not alter BP in their study, the authors concluded that accurate perception of blinded assignment did not impact outcomes, although results were not compared in volunteers who correctly identified their assignment with those who did not. 
BP Measurement Methodology
There are considerable variations in BP methods reported in 13 peer-reviewed reports on dark chocolate and BP. Among open-label studies, the Omron HEM 722C monitor used by Taubert et al 19, 22 received an "A" rating for accuracy using the British Hypertension Society protocol. 37 The SpaceLabs 90207 ambulatory BP monitor used in 2 of the studies by Grassi et al 21, 23 received a "B" rating for accuracy for both systolic and diastolic BPs. 38 The limited accuracy of the SpaceLabs ambulatory monitor for measuring changes in mean systolic and diastolic BPs is mitigated by obtaining a large number of measurements over 24 hours.
Using the SpaceLabs 90207 for 4 laboratory BP readings in a double-blind study of dark chocolate and BP is a greater concern given the limited number of measurements. 28 Two double-blind studies 26, 27 used the previous-generation Dinamap, which received grades of "C" or lower for BP accuracy. 39 Another double-blind study did not describe the BP measurement device, position of volunteers, or number of readings. 30 The doubleblind study by Muniyappa et al 29 reported acceptable BP measurement methods. The study by Crews et al 30 also appeared to use accepted BP measurement methodology.
In summary, open-label studies reporting that dark chocolate lowered BP generally described well-accepted methods for measuring BP. In contrast, except for 2 reports, 29, 31 double-blind studies provided limited detail or used devices with suboptimal accuracy.
Brand of Dark Chocolate
Four open-label studies selected Ritter dark chocolate with 50% cocoa, and all 4 documented significant BP reduction (Tables 1 and 2 ). In 3 studies, 100 g with 50% cocoa and 480 kcal were given daily for 14 to 15 days. 19 -21 Systolic BP declined 5 to 11 mm Hg after 2 weeks. In the fourth study, the daily dose was 6.3 g of dark chocolate with Ϸ30 calories and 3.1 g cocoa daily. 22 Systolic BP declined 2.9 mm Hg after 18 weeks, which was statistically significant. Low-"dose" Ritter dark chocolate did not lower BP significantly at 6 and 12 weeks. Thus, Ritter dark chocolate with 50.0 g of cocoa daily appears to lower BP more rapidly and to a greater extent than 3.1 g cocoa daily. However, the large dose (Ϸ480 kcal) would constitute Ϸ20% to 25% of total daily calories for most people, which may be impractical long term.
Four double-blind studies selected Mars dark chocolate. 26 
Variations in Chemical Content of Dark Chocolate/Cocoa and Biological Implications
Cocoa is rich in flavanols (mainly epicatechin) and their polymeric form, procyanidins. Flavanols, especially epicatechin, appear responsible for several beneficial effects of cocoa/chocolate. 11 In a landmark study, epicatechin was strongly linked to beneficial effects on vascular endothelial function. 13 The extant literature provides few clues on the mechanism(s) by which some cocoa products appear to lower BP. In vitro studies have not provided convincing evidence that a particular component or components of dark chocolate/cocoa lower BP. 40 As one potential mechanism, angiotensin-converting enzyme inhibitors are effective antihypertensive agents, and procyanidins in cocoa and specific flavanols in other foods inhibit angiotensin-converting enzyme activity in vitro. 41 The lowest flavanol concentrations used in the in vitro studies, however, are much higher than those expected after consuming chocolate.
In a recent preliminary report, epicatechin induced a dosedependent reduction of BP in an animal model of hypertension induced by inhibiting NO synthase, 42 which coincides with the study by Taubert et al 22 showing that dark chocolate increased an NO biomarker in humans. However, there is no apparent correlation between the epicatechin content of dark chocolate/ cocoa studied and BP change. The variable effects of dark chocolate/cocoa on BP may reflect differences in content of chemicals that lower BP and/or others that raise BP, for example, 5-fold differences in the epicatechin:catechin ratio. 43 Those chemical differences could reflect variations in cocoa bean genetics or processing (Figure 2 ). Genetic and differences in cocoa beans can explain up to 4-fold differences in flavanol content. 35 Theobroma cocao is grown mainly on small farms near the equator. Beans from several small farms are combined, where they typically undergo initial processing. The chemical composition of cocoa beans varies based on cultivar (ie, genetics), as well as geographical location and seasonal environmental changes. 25 and the mean systolic and diastolic BPs are shown for the 2 groups combined in the study by Ried et al. 24 Most producers purchase beans from several countries and blend beans for their products. 36 Even the same manufacturer may use a different blend of beans for its products, for example, Ritter's 50% and 71% dark chocolates. 44 Most producers do not report their source(s) of cocoa beans. Variations in cocoa bean processing can dramatically alter chemical composition of the final product. Fermentation, roasting, and alkali treatment, while improving flavor, reduce flavanol content. 35, 36 Cocoa processing could produce compound(s) that counteract its BP-lowering effects analogous to coffee processing. Green coffee bean (unroasted) extracts lower BP. 45, 46 The BP effects appear to be mediated by chlorogenic acid and related hydroxycinnamates. 47, 48 However, roasting coffee beans produces hydroxyhydroquinone that negates the BP-lowering effects of coffee (Figure 2) . [45] [46] [47] [48] Although chocolate contains epicatechin and catechin, T cacoa produces very little catechin. The (Ϫ)-catechin is formed by epimerization of (Ϫ)-epicatechin during processing ( Figure  2 ). The content of (Ϫ)-catechin varies widely between chocolate products, which provides indirect evidence for variability in processing techniques. 43 Although little is known about biological activity of (Ϫ)-catechin, the 2 enantiomers showed opposite effects on glycogen metabolism in isolated rat hepatocytes. 49 Femoral artery vasodilation in rats was observed after a bolus of 10 nM (Ϫ)-epicatechin, but no effect was observed using concentrations of (Ϫ)-catechin Յ1000 nM. 50 Although the contribution of (Ϫ)-catechin to chocolate's BP effect is unclear, it appears plausible that (Ϫ)-catechin counteracts BP-lowering effects of (Ϫ)-epicatechin and may explain the lack of BP effects in some cocoa studies.
Vasodilators Are Not Always Antihypertensive
In most hypertensives, elevated BP is linked with increased vascular resistance. 51 It is sometimes assumed that reducing vascular resistance will always lower BP. Although peripheral vasodilators can lead to short-term BP reduction, the kidney is overwhelmingly the dominant controller of long-term BP. 52 Unless the renal pressure threshold for maintaining sodium homeostasis is set at a lower level either by direct or indirect actions on the kidney, then long-term BP will not change significantly. Thus, cocoa's vasodilatory effects will not produce sustained reductions in BP unless resetting of the renal threshold for pressure natriuresis to a lower level occurs. 52 
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Unanswered Questions
Several unanswered questions must be addressed before dark chocolate can be recommended as a lifestyle intervention for hypertension and prehypertension. A qualitative analysis of participant "lived experiences" in clinical trials of chocolate is needed to better understand the individual and social contexts of the trial, adherence to eating different dark chocolates, and feasibility of widespread adoption. In the study by Ried et al, 24 73% of subjects indicated they would consume 50 g of dark chocolate daily as a long-term intervention, including a substantial minority that was not thrilled with the idea. This finding suggests that a large proportion of hypertensives and prehypertensives would consume a relatively large amount of dark chocolate if important health benefits are established.
Perspective
Prehypertension and hypertension affect approximately two thirds of US adults. Lifestyle interventions are foundational therapy for all hypertensives and the only intervention recommended for most prehypertensives. Several lifestyle options lower BP and improve other cardiovascular risk factors, but population effectiveness is limited because of low adoption and maintenance. Historical, ecological, and clinical trial evidence suggest that dark chocolate can improve insulin sensitivity and vascular endothelial function and possibly lower BP. Several open-label studies reported that dark chocolate lowered BP among volunteers with a wide range of ages and baseline BPs. These studies suggest that dark chocolate could be useful for the prevention and management of hypertension in a broad segment of the population.
Addressing the unanswered questions through high-quality research has potential to establish that dark chocolate/cocoa lowers BP and to optimize its antihypertensive effects while retaining and even amplifying other beneficial actions. The research portfolio should seek to identify adverse effects of dark chocolate and to define the proportion of the at-risk population for whom it is an acceptable long-term intervention. Addressing the unanswered questions may lead to a palatable recommendation for reducing cardiovascular risk for millions of prehypertensive and hypertensive people.
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